Published in Stroke on September 07, 2006
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Immediate and one-year outcome of patients presenting with acute coronary syndrome complicated by stroke: findings from the 2nd Gulf Registry of Acute Coronary Events (Gulf RACE-2). BMC Cardiovasc Disord (2012) 0.80
Importance and repercussions of renal and cardiovascular pathology on stroke in young adults: an anatomopathologic study of 52 clinical necropsies. Clinics (Sao Paulo) (2008) 0.77
Acute myocardial infarction, ischemic stroke, sympathetic stress, and inflammation: birds of a feather. Stroke (2006) 0.75
Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome? Open Heart (2014) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med (2005) 5.49
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med (2004) 4.18
Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA (2012) 3.66
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr (2007) 3.49
Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45
Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA (2011) 3.44
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA (2007) 3.28
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation (2006) 2.72
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA (2005) 2.56
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J (2008) 2.33
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum (2007) 2.27
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol (2007) 1.97
Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation (2011) 1.95
Achieving door-to-balloon times that meet quality guidelines: how do successful hospitals do it? J Am Coll Cardiol (2005) 1.79
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Use of emergency medical services in acute myocardial infarction and subsequent quality of care: observations from the National Registry of Myocardial Infarction 2. Circulation (2002) 1.76
Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol (2006) 1.75
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol (2010) 1.71
Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol (2005) 1.69
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation (2007) 1.67
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol (2007) 1.66
Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol (2004) 1.64
Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol (2008) 1.62
Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol (2006) 1.61
Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr (2008) 1.60
Outcomes among patients with non-ST-segment elevation myocardial infarction presenting to interventional hospitals with and without on-site cardiac surgery. JACC Cardiovasc Interv (2009) 1.58
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv (2009) 1.56
Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol (2002) 1.55
Choice of reperfusion strategy at hospitals with primary percutaneous coronary intervention: a National Registry of Myocardial Infarction analysis. Circulation (2009) 1.55
Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol (2004) 1.52
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur Heart J (2009) 1.49
Long-term outcomes of plaque debulking with rotational atherectomy in side-branch ostial lesions to treat bifurcation coronary disease. J Invasive Cardiol (2009) 1.47
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47
Smallpox vaccination and ischemic coronary events in healthy adults. Vaccine (2007) 1.43
Fractionating heparins and their clinical trial data--something for everyone. JAMA (2004) 1.41
Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: total and incremental estimates. Arthritis Rheum (2004) 1.41
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. J Thromb Thrombolysis (2012) 1.41
Variable response to antiplatelet therapy: what does it mean to clinicians? Cleve Clin J Med (2007) 1.40
Review of subacute stent thrombosis following percutaneous coronary intervention at a low-volume catheterization laboratory. J Interv Cardiol (2005) 1.40
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study. Clin Drug Investig (2008) 1.40
A framework for modelling fertility motivation in couples. Popul Stud (Camb) (2004) 1.39
Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol (2008) 1.39
Relation of platelet inactivation with intravenous glycoprotein IIb/IIIa antagonists to major bleeding (from the GOLD study). Am J Cardiol (2002) 1.37
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. Circulation (2006) 1.35
Endometriosis fertility index: the new, validated endometriosis staging system. Fertil Steril (2010) 1.34
Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol (2008) 1.30
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv (2011) 1.26
Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE. J Urol (2003) 1.25
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol (2010) 1.23
Door-to-drug and door-to-balloon times: where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). Am Heart J (2006) 1.21
Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res (2011) 1.21
Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina (2009) 1.20
Efficacy of osteopathic manipulation as an adjunctive treatment for hospitalized patients with pneumonia: a randomized controlled trial. Osteopath Med Prim Care (2010) 1.19
Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med (2004) 1.17
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation (2003) 1.14
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation (2008) 1.14
The association of sex and payer status on management and subsequent survival in acute myocardial infarction. Arch Intern Med (2002) 1.14
Impact of socioeconomic status, race, and ethnicity on quality of life in patients with cystic fibrosis in the United States. Chest (2009) 1.11
G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008) 1.10
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol (2006) 1.09
Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol (2004) 1.09
The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol (2009) 1.07
Coronary thrombus detected by cardiac CT angiography before cardiac catheterization. J Thorac Imaging (2010) 1.07
Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J (2008) 1.07
Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol (2003) 1.06
Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol (2011) 1.06
Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol (2011) 1.06
Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE. J Urol (2004) 1.04
Mortality following defibrillator implantation in patients with renal insufficiency. J Cardiovasc Electrophysiol (2006) 1.03
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J (2012) 1.02
Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros (2013) 1.00
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol (2005) 1.00
Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol (2010) 1.00
Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros (2010) 1.00
Differences in symptom presentation and hospital mortality according to type of acute myocardial infarction. Am Heart J (2012) 1.00
The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol (2005) 1.00
Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis. J Pediatr (2011) 0.99